FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Roger Aoki

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Procedures

Co-author Network

Publications

TOP 3
Gary W Lawrence; Saak V Ovsepian; Jiafu Wang; K Roger Aoki; J Oliver Dolly
Therapeutic effectiveness of botulinum neurotoxin A: Potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25.
Jiafu Wang; Larry Wheeler; Tomas H Zurawski; K Roger Aoki; Gary W Lawrence; Jianghui Meng; J Oliver Dolly
Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis.
Jiafu Wang; Tomas H Zurawski; Jianghui Meng; K Roger Aoki; Sanjay Boddul; MacDara O Bodeker; J Oliver Dolly
Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Roger Aoki (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Gary W Lawrence; Saak V Ovsepian; Jiafu Wang; K Roger Aoki; J Oliver Dolly
Therapeutic effectiveness of botulinum neurotoxin A: Potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25.
Neuropharmacology 2013;70():287-95.
2012: Jiafu Wang; Larry Wheeler; Tomas H Zurawski; K Roger Aoki; Gary W Lawrence; Jianghui Meng; J Oliver Dolly
Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2012;26(12):5035-48.
2012: Jiafu Wang; Tomas H Zurawski; Jianghui Meng; K Roger Aoki; Sanjay Boddul; MacDara O Bodeker; J Oliver Dolly
Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
The Biochemical journal 2012;444(1):59-67.
2012: M Zouhair Atassi; Behzod Z Dolimbek; Lance E Steward; K Roger Aoki
Antibodies against a synthetic peptide designed to mimic a surface area of the H chain of botulinum neurotoxin A.
Immunology letters 2012;142(1-2):20-7.
2012: Ester Fernández-Salas; Birgitte P S Jacky; Yanira Molina; Jeremy B Nelson; Joanne Wang; K Roger Aoki
Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay.
PloS one 2012;7(11):e49516.
2012: M Zouhair Atassi; Behzod Z Dolimbek; Minako Oshima; K Roger Aoki
Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains.
Immunobiology 2012;217(1):1-7.
2012: M Zouhair Atassi; Joseph Jankovic; Lance E Steward; K Roger Aoki; Behzod Z Dolimbek
Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
Immunobiology 2012;217(1):17-27.
2011: Minako Oshima; K Roger Aoki; Philip R Deitiker; Drake D Duane; Joseph Jankovic; M Zouhair Atassi
Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
Journal of neuroimmunology 2011;240-241():121-8.
2011: K Roger Aoki; Joseph Francis
Updates on the antinociceptive mechanism hypothesis of botulinum toxin A.
Parkinsonism & related disorders 2011;17 Suppl 1():S28-33.
2011: Minako Oshima; K Roger Aoki; Philip R Deitiker; Drake D Duane; Joseph Jankovic; M Zouhair Atassi
Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients.
Journal of neuroimmunology 2011;237(1-2):66-72.
2011: M Zouhair Atassi; Behzod Z Dolimbek; Joseph Jankovic; Lance E Steward; K Roger Aoki
Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies.
Immunobiology 2011;216(7):782-92.
2011: Behzod Z Dolimbek; K Roger Aoki; M Zouhair Atassi
Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates.
Immunology letters 2011;137(1-2):46-52.
2011: Justin A Ross; Marcella A Gilmore; Dudley Williams; K Roger Aoki; Lance Steward; David Jameson
Characterization of Förster resonance energy transfer in a botulinum neurotoxin protease assay.
Analytical biochemistry 2011;413(1):43-9.
2011: Behzod Z Dolimbek; Lance E Steward; K Roger Aoki; M Zouhair Atassi
Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A: antigenic structure of the entire toxin.
Immunobiology 2011;216(6):698-706.
2011: Philip R Deitiker; Minako Oshima; Joseph Jankovic; Drake D Duane; K Roger Aoki; M Zouhair Atassi
Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans.
Autoimmunity 2011;44(3):167-76.
2010: Gary W Lawrence; K Roger Aoki; J Oliver Dolly
Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers.
The Journal of pharmacology and experimental therapeutics 2010;334(3):1080-6.
2010: M Zouhair Atassi; Behzod Z Dolimbek; Lance Steward; K Roger Aoki
Inhibition of botulinum neurotoxin a toxic action in vivo by synthetic synaptosome- and blocking antibody-binding regions.
The protein journal 2010;29(5):320-7.
2009: Jianghui Meng; Saak V Ovsepian; Jiafu Wang; Mark Pickering; Astrid Sasse; K Roger Aoki; Gary W Lawrence; J Oliver Dolly
Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2009;29(15):4981-92.
2008: Behzod Z Dolimbek; Lance Steward; K Roger Aoki; M Zouhair Atassi
The binding sites on botulinum neurotoxin B for synaptotagmin and for blocking antibodies.
Biochemical and biophysical research communications 2008;376(3):631-2.
2008: M Zouhair Atassi; Behzod Z Dolimbek; Joseph Jankovic; Lance Steward; K Roger Aoki
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment.
Molecular immunology 2008;45(15):3878-88.
2008: Jiafu Wang; Jianghui Meng; Gary W Lawrence; Tomas H Zurawski; Astrid Sasse; MacDara O Bodeker; Marcella A Gilmore; Ester Fernández-Salas; Joseph Francis; Lance Steward; K Roger Aoki; J Oliver Dolly
Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics.
The Journal of biological chemistry 2008;283(25):16993-7002.
2008: Christopher P Smith; David A Gangitano; Alvaro Munoz; Nilson A Salas; Timothy B Boone; K Roger Aoki; Joseph Francis; George Somogyi
Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury.
Neurochemistry international 2008;52(6):1068-75.
2008: Behzod Z Dolimbek; Lance Steward; K Roger Aoki; M Zouhair Atassi
Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin.
Molecular immunology 2008;45(4):910-24.
2008: K Roger Aoki; Ryan Irvine; Conor Gallagher
Re: Botox produces functional weakness in non-injected muscles adjacent to the target muscle.
Journal of biomechanics 2008;41(9):2066-7; author reply 2067.
2007: Behzod Z Dolimbek; K Roger Aoki; Lance Steward; Joseph Jankovic; M Zouhair Atassi
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
Molecular immunology 2007;44(5):1029-41.
2007: M Zouhair Atassi; Behzod Z Dolimbek; Lance Steward; K Roger Aoki
Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action.
Critical reviews in immunology 2007;27(4):319-41.
2007: Gary Lawrence; Jiafu Wang; C K N Kwo Chion; K Roger Aoki; J Oliver Dolly
Two protein trafficking processes at motor nerve endings unveiled by botulinum neurotoxin E.
The Journal of pharmacology and experimental therapeutics 2007;320(1):410-8.
2007: M Zouhair Atassi; Behzod Z Dolimbek; Philip R Deitiker; Joseph Jankovic; K Roger Aoki
A peptide-based immunoassay for antibodies against botulinum neurotoxin A.
Journal of molecular recognition : JMR 2007;20(1):15-21.
2006: J Oliver Dolly; K Roger Aoki
The structure and mode of action of different botulinum toxins.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2006;13 Suppl 4():1-9.
2006: Takahiro Maruta; Behzod Z Dolimbek; K Roger Aoki; M Zouhair Atassi
Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: a new assay for blocking and non-blocking antibodies.
Journal of neuroscience methods 2006;151(2):90-6.
2005: M Zouhair Atassi; Gulnoz S Dolimbek; Philip R Deitiker; K Roger Aoki; Behzod Z Dolimbek
Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A.
Molecular immunology 2005;42(12):1509-20.
2005: K Roger Aoki
Pharmacology and immunology of botulinum neurotoxins.
International ophthalmology clinics 2005;45(3):25-37.
2005: Gulnoz S Dolimbek; Behzod Z Dolimbek; K Roger Aoki; M Zouhair Atassi
Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains.
Immunological investigations 2005;34(2):119-42.
2004: K Roger Aoki
Botulinum toxin: a successful therapeutic protein.
Current medicinal chemistry 2004;11(23):3085-92.
2004: Takahiro Maruta; Behzod Z Dolimbek; K Roger Aoki; Lance Steward; M Zouhair Atassi
Mapping of the synaptosome-binding regions on the heavy chain of botulinum neurotoxin A by synthetic overlapping peptides encompassing the entire chain.
The protein journal 2004;23(8):539-52.
2004: Ester Fernández-Salas; Lance Steward; Helen Ho; Patton E Garay; Sarah W Sun; Marcella A Gilmore; Joseph V Ordas; Joanne Wang; Joseph Francis; K Roger Aoki
Plasma membrane localization signals in the light chain of botulinum neurotoxin.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(9):3208-13.
2004: Ester Fernández-Salas; Helen Ho; Patton Garay; Lance Steward; K Roger Aoki
Is the light chain subcellular localization an important factor in botulinum toxin duration of action?
Movement disorders : official journal of the Movement Disorder Society 2004;19 Suppl 8():S23-34.
2004: Wolfgang H Jost; K Roger Aoki
Botulinum toxin A in anal fissure: why does it work?
Diseases of the colon and rectum 2004;47(2):257-8.
2003: K Roger Aoki
Pharmacology and immunology of botulinum toxin type A.
Clinics in dermatology 2003;21(6):476-80.
2003: Li Zhang; Wei-Jen Lin; Shengwen Li; K Roger Aoki
Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain.
Gene 2003;315():21-32.
2003: Diane D-S Tang-Liu; K Roger Aoki; J Oliver Dolly; Anton de Paiva; Tara L Houchen; Leslie F Chasseaud; Colin Webber
Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution.
Toxicon : official journal of the International Society on Toxinology 2003;42(5):461-9.
2003: K Roger Aoki
Evidence for antinociceptive activity of botulinum toxin type A in pain management.
Headache 2003;43 Suppl 1():S9-15.
2003: Stephen D Silberstein; K Roger Aoki
Botulinum toxin type A: myths, facts, and current research.
Headache 2003;43 Suppl 1():S1.
2003: Patrick G Foran; Nadiem Mohammed; Godfrey O Lisk; Sharuna Nagwaney; Gary W Lawrence; Eric Johnson; Leonard Smith; K Roger Aoki; J Oliver Dolly
Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons.
The Journal of biological chemistry 2003;278(2):1363-71.
2002: K Roger Aoki
Physiology and pharmacology of therapeutic botulinum neurotoxins.
Current problems in dermatology 2002;30():107-16.
1999: A de Paiva; Frederic A Meunier; Jordi Molgó; K Roger Aoki; J Oliver Dolly
Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(6):3200-5.